Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

CTA approval for ARGX-112 triggers milestone payment to Argenx

April 13, 2018

Phase II ATOMIK study of serlopitant does not meet primary or key secondary efficacy endpoints

April 9, 2018

Krystal files IND with FDA for phase I/II study of KB-103 for dystrophic EB

March 28, 2018

Genentech develops anti-inflammatory nuclear receptor ROR-gamma inverse agonists

March 26, 2018

Bristol-Myers Squibb discovers new Toll-like receptor 7, 8 and 9 antagonists

March 26, 2018

Processa Pharmaceuticals assigned license for CTP-499

March 23, 2018

First patient dosed in phase II psoriasis trial of ABY-035

March 22, 2018

FDA approves Ilumya for moderate to severe plaque psoriasis

March 21, 2018

SNA-125 begins proof-of-concept trial in atopic dermatitis

March 13, 2018

European Commission approves Ameluz with daylight PDT

March 7, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 22, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
Insilico Medicine synthesizes new Nav1.8 blockers
BioWorld Science
Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.